Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia

Acute Myeloid Leukemia Clinical Trial

— NAKIP-AML  

Official title:

Natural Killer Cell Immunotherapy in Combination With PARP-inhibition to Overcome NKG2D Mediated Immune Evasion in Acute Myeloid Leukemia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05319249
• Other study ID #: NAKIP_01_2022
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: June 2024
• Est. completion date: June 2028

Study information

• Verified date: April 2024
• Source: German Cancer Research Center
• Contact: Carsten Müller-Tidow, Prof. Dr.
• Phone: +49622156
• Email: carsten.mueller-tidow[@]med.uni-heidelberg.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Therapy resistance remains the major obstacle to cure in many types of cancer. In particular in leukemia, therapy resistance depends on leukemic stem cells (LSC) that exhibit inherent therapy resistance to multiple drugs and contribute to overt leukemic relapse. Cellular therapies alone or in combination with other targeted or chemotherapeutic approaches can overcome drug mediated therapy resistance and induce long lasting remissions. Several trials have shown that adoptive transfer of allogeneic NK cells can induce clinical remission in patients with myeloid malignancies. In addition, the antileukemic efficacy of alloreactive NK cells has been shown to facilitate cure after T cell depleted haploidentical stem cell transplantation. Recently, it was demonstrated that absence of NKGD2 ligand expression on leukemic stem cells determines therapy resistance and immune escape towards NK cells in AML. PARP1 inhibitors can induce re-expression of NKG2D ligands. This phase I/II clinical trial will evaluate the combination of NK cell therapy and PARP inhibition by Talazoparib in patients with poor prognosis AML as characterized by Minimal Residual Disease (MRD) or overt relapse with less than 20% bone marrow blasts. The hypothesis that allogeneic NK cell therapy combined with PARP inhibition will increase the response rate (CR/CRi for relapsed/ refractory patients and MRD-response for MRD positive patients) from 35% to 60% will be tested. The co-primary endpoints are i) response to treatment defined as complete remission (CR) for patients with overt leukemia at time of inclusion and MRD decrease >1log10 for patients with rising MRD at time of inclusion as well as ii) safety and feasibility of the protocol. Key secondary endpoints are event free survival and overall survival. Two cohorts will be assessed independently: patients with i) overt leukemia and ii) patients with rising MRD at time of inclusion. Safety and feasibility will be analyzed continuously during the entire trial. The NAKIP-AML trial will analyze efficacy and feasibility of NK cell transplantation together with PARP1 inhibition.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 54
• Est. completion date: June 2028
• Est. primary completion date: June 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with confirmed diagnosis of AML according to WHO-2016 (Arber, Orazi et al. 2016) (except acute promyelocytic leukemia) with either de novo AML, AML after preceding myelodysplastic or myeloproliferative syndrome (MDS/MPD), and therapy- related AML (t-AML) after previous cytotoxic therapy or radiation are eligible.

A) Relapsed or Refractory AML with less than 20% bone marrow blasts and less than 20% blasts in peripheral blood.

B) Rising MRD levels (>3 fold) as detected by either molecular genetics or flow cytometry in patients still in hematologic remission.

2. Patients who received at least one line of AML therapy. This is defined as either stem cell transplantation or intensive AML therapy or palliative AML therapy containing at least one of the following drugs Azacitidine, Decitabine, Cytarabine, Venetoclax or an FLT3 inhibitor..

3. Discontinuation of prior AML treatment before the start of study treatment for at least 107 days for cytotoxic agents and = 53 half-lives for non-cytotoxic / investigational drug treatment preceding the first dose of trial medications.

4. Age = 18 years

5. ECOG =2

6. Pregnancy and childbearing potential:

• Non-pregnant and non-nursing women of childbearing potential must have a negative serum or urine ß-HCG pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration. ("Women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months).

• Female patients of reproductive age must agree to avoid getting pregnant while on therapy.

• Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin highly effective methods (referring to recommendation of the CTFG) of birth control during study and at least 6 months (women), after end of treatment.

• Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy and must agree to avoid to father a child during study and until 6 months after end of treatment.

7. Willingness of patients to adhere to protocol specific requirements and capacity to give written informed consent

8. Ability of patient to understand the character and individual consequences of clinical trial

9. Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out.

10. Suitable donor for NK cell transplantation

Exclusion Criteria:

Patients presenting with any of the following criteria will not be included in the trial:

1. Acute promyelocytic leukemia (AML M3)

2. AML in which less than 10% of the blasts express the CD34 surface marker expression as analyzed at the local laboratory.

3. Known central nervous system manifestation of AML

4. Uncontrolled or significant cardiovascular disease, including any of the following:

• Heart failure NYHA class 3 or 4

• Left ventricular ejection fraction (LVEF) = 40% by echocardiogram ECHO)

• History of uncontrolled angina pectoris or myocardial infarction within 12 months prior to screening

• History of second (Mobitz II) or third-degree heart block or any cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)

5. Pregnant or nursing women

6. Chronically impaired renal function (creatinine clearance < 30 ml / min)

7. Organ dysfunction (e.g. liver, kidney, lung, heart) which in the opinion of the treating physician decreases life expectancy to less than three months.

8. Kidney failure with a calculated glomerular filtration rate <30 ml/min or bilirubin >2-fold the upper reference limit of the local laboratory.

9. HIV infection and/or active hepatitis B or C infection (active hepatitis B defined by HBs Ag positivity, anti HBs positivity or anti-HBC positivity, active hepatitis C defined by positive virus load).

10. Evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy

11. Uncontrolled active infection

12. Concurrent malignancies other than AML with an estimated life expectancy of less than two years

13. Known hypersensitivity to PARP inhibitors

14. Isolated extramedullary manifestation of AML

15. Patients < 100 days after allogeneic stem cell transplantation at the time of screening

16. Expected non-compliance of patient

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Biological:
• NK cells
NK cells will be given as a single intravenous infusion.

Drug:
• Talazoparib 1 MG [Talzenna]
Subjects will receive treatment with Talazoparib capsules 1 mg/day (4 days) with subsequent intravenous NK cell infusion.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
German Cancer Research Center

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	complete remission (CR/CRi)	response defined as complete remission (CR/CRi) for patients with overt leukemia at time of inclusion and MRD decrease >1log10 for patients with rising MRD at time of inclusion.	Collected at a minimum at baseline, day 28 and latest on day 42
Secondary	EFS - Event-free survival	Event-free survival	EFS is defined as the time of entry into the study to the date of primary refractory disease, or relapse from CR, or CRi, or death from any cause, whichever comes first, assessed up to 42 days.
Secondary	RFS -Relapse-free survival	RFS is defined only for patients achieving CR or CRi	Defined as the time from achieving a remission until the date of relapse or death from any cause, whichever comes first, assessed up to 42 days.
Secondary	OS - Overall survival	Overall survival	OS is defined as the time from entry into the trial to the date of death from any cause, assessed up to 42 days.
Secondary	MRD	Measurable Residual Disease	Collected at a minimum at baseline, day 28 and latest on day 42
Secondary	QoL - Quality of life - QLQ-C30	Validated 30-item self-assessment questionnaire to assess quality of life aspects. The items are rated on a 4-point Likert scale ranging from 1 (not at all) to 4 (very much) with higher scores meaning a higher level of fatigue.	QoL is assessed at baseline and latest on day 42.